Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | VLA15-221 | Lyme disease | Phase 3 | Data Released | Intramuscular | Antibiotic |
| Pfizer Inc. | Abrocitinib - (JADE DARE) | Atopic dermatitis | Phase 3 | Oral | Immunology | |
| Pfizer Inc. | BNT161 | Influenza Vaccine | Phase 3 | Intramuscular | Immunology | |
| Pfizer Inc. | Inclacumab (GBT2104-131) - (THRIVE) | Sickle Cell Disease | Phase 3 | Data Released | Intravenous | Hematology |
| Pfizer Inc. | Etrasimod - (ELEVATE 12) | Ulcerative colitis | Phase 3 | Oral | Gastroenterology | |
| Pfizer Inc. | BAVENCIO (avelumab) - (JAVELIN Head and Neck100) | Head and Neck Cancer | Phase 3 | Intravenous | Oncology | |
| Pfizer Inc. | BAVENCIO (avelumab) - JAVELIN Gastric 100 | Gastric cancer | Phase 3 | Intravenous | Oncology | |
| Pfizer Inc. | Tucatinib + ado-trastuzumab emtansine (T-DM1, Kadcyla), - (HER2CLIMB-02) | HER2+ Metastatic Breast Cancer (MBC) | Phase 3 | Data Released | Oral and intravenous | Oncology |
